Finding Biomarkers for Early Alzheimer’s Detection

Savannah Snider, Stephanie Jones, Dr. Enid Sisskin, Dr. Rodney Guttmann, Biology, University of West Florida, 11000 University Pkwy, Pensacola, FL 32514

Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is always fatal.  AD is pathologically defined by the presence of amyloid plaques composed of the Abeta peptide, and neurofibrillary tangles composed primarily of the microtubule-associated protein tau. There are no current treatments or cures for AD and no new therapies have been approved in 20 years. One hypothesis for these failures is that the experimental treatment does not begin until late in the disease and the level of neurodegeneration is too substantial to be reversed. Thus, a major objective is to identify people earlier in disease progression, so that experimental drugs can be tested during the preclinical stages. The purpose of the current research is to identify a biomarker within human cerebral spinal fluid that would be used for early detection of AD. To attain this goal, we have used a phage-peptide display to screen for the presence of abnormal forms of tau protein. Because tau is so closely correlated with AD progression, we hypothesize that post-translational changes to tau represent a rational target for further biomarker development. ELISA screening is conducted to validate lead candidate phages and compare them to currently available CSF biomarkers.

Additional Abstract Information

Presenter: Savannah Snider

Institution: University of West Florida

Type: Poster

Subject: Biology

Status: Approved

Time and Location

Session: Poster 3
Date/Time: Mon 4:30pm-5:30pm
Session Number: 3105